Agro groups: Derailing GM fish review would dent FDA’s credibility

More than 30 agricultural organizations have signed a letter to Congressional leaders urging them to allow the Food and Drug Administration (FDA) to complete its review of the world’s first genetically engineered fish for human consumption.

The move follows a recent amendment
to the Agriculture Appropriations Bill (HR2112) that would stop the FDA from spending appropriated funds to finalize its review of the fish.

AquaBounty Technologies’ AquAdvantage Atlantic salmon includes a gene from the faster-growing Pacific Chinook salmon, which enables it to reach maturity twice as quickly as standard Atlantic salmon.

In the letter, addressed to John Boehner, Nancy Pelosi, Harry Reid and Mitch McConnell, the authors call on Congress to reject the amendment, which was approved by voice on June 15 with only a handful of the House of Representatives’ 435 members in attendance.

Science-based review should not be subject to political intervention

Preventing regulators from completing their assessment of the fish would dent the credibility of the FDA’s science-based approval process, claimed the letter’s 38 signatories, which included the American Meat Institute and the Biotechnology Industry Organization (BIO).

“We do not write to support or oppose this specific application, but rather to register our concern with the House’s action, which if allowed to become law, would disrupt the FDA’s Congressional mandate to base its assessments of human and animal drugs, devices, vaccines, and process applications on the best-available science.”

The authors also cite comments from Dr Calestous Juma of Harvard’s Kennedy School of Government made at a recent hearing on agricultural biotechnology:

“It is not this particular fish that is at stake. It is the principle behind the amendment and its wider ramifications. It sends the message to the rest of the world that the science-based regulatory oversight as embodied in the FDA review process is subject to political intervention.”

‘Frankenstein’ fish…

The amendment to block the approval process was proposed by House Republican Don Young from Alaska, who argues the transgenic salmon could threaten wild salmon populations (a claim that has been consistently denied by AquaBounty).

Speaking in the House on June 15, he said: “It's crucially important we understand that this should not be allowed, for the FDA to say, okay, a genetically raised salmon - I call it a Frankenstein fish - should never be allowed in our markets.”

He was backed by Congressman Sam Farr (Dem-CA), who claimed the fish could have “grave, unintended consequences on human health. Preliminary studies show that the compounds in genetically engineered salmon may be linked to cancer and severe drug allergies.”

However, Congressman Jack Kingston (Rep-GA) urged the House to allow the FDA to make a science-based assessment.

“We’re constantly getting on the FDA to use more sound science, less politics, and to have more transparency, and it appears that that's what they're doing here. And they may come out against genetically modified salmon, but they are just looking at it right now to determine.”

A dangerous precedent?

Interfering with the regulatory process in this way would also set a dangerous precedent, warned BIO chief executive Jim Greenwood.

“Disrupting FDA’s science-based assessment process based on non-scientific political concerns would set a dangerous precedent in our country. It is critical that the scientific experts who work within FDA be allowed to conduct comprehensive scientific approvals without political influence.”

AquaBounty chief executive Ronald Stotish has also become increasingly frustrated
by the intervention of politicians in the regulatory process, recently accusing senators trying to derail the approval process of “willfully ignoring science-based research” and spreading “misinformed paranoia
”.

As the politicians in question were well aware, he said, the transgenic salmon were sterile, exclusively-female, and unable to breed even if they did escape from enclosed, FDA-regulated facilities into the wild.

“The data is out there – although it has been ignored by all of the opposition groups – the FDA has already concluded that there is no food safety or environmental risk. But a science-based review process is being threatened by political shenanigans.”

In its analysis
of the AquaBounty technology published last September, the FDA said: "The food from AquAdvantage Salmon that is the subject of this application is as safe as food from conventional Atlantic salmon... In addition, no effects on stocks of wild Atlantic salmon are expected.”

This content is copyright protected

However, if you would like to share the information in this article, you may use the headline, summary and link below:

More than 30 agricultural organizations have signed a letter to Congressional leaders urging them to allow the Food and Drug Administration (FDA) to complete its review of the world’s first genetically engineered fish for human consumption.

3 comments(Comments are now closed)

GM FISH

Clinically tested farm food is not contributing to good health. Combining this with clinically tested GM food in any form is only adding to a deepening deterioration in health concerns.

Report abuse

Posted by harry06 September 2011 | 10h422011-09-06T10:42:46Z

It's not politics vs. science; it's politics vs. politics

The assertion that the FDA's review is purely scientific is absurd. Their process is stacked to favor producers. The FDA analysis isn't based on objective based on research. The "research" was conducted by Aquabounty, the very party with a financial stake in the outcome. Moreover, Aquabounty has no obligation to forward all their results to the FDA; only the data they feel supports their case. This is analogous to ruling on the dangers of tobacco based on the "research" conducted by the tobacco industry.
Even under these "stacked deck" conditions, the report the FDA generated from analyzing their research raises tons of questions. One of the biggest issues is the small number of subjects (i.e., fish) they used in groups used to compare "normal" fish to their GMO fish. In many cases the comparison groups contained only 6 subjects. Tiny group size makes it almost impossible for differences between groups to be statistically significant, which stacks the deck in favor of concluding there is "no difference" between the test groups. This is nothing more than deliberately shoddy science.
As for the assertion that all their stock will be sterile females, the FDA found that 5% of their genetically modified eggs are fertile and can reproduce. In the case of accidental release of their stock into the wild, this puts natural stock at risk.
So, these politicians that are challenging the status quo review process are merely countering an already political process, and they are representing not only those with opposed financial interests, they are speaking for humanity and the environment, both of which are put at risk by not being careful in this matter.

Report abuse

Posted by Jon09 August 2011 | 15h302011-08-09T15:30:32Z

aiready questioned

The credibility of the FDA is already questioned because of its past . Too often , because of political presure , the FDA has accepted the research data of a pationing group over doing its own research . That is not the way it is supposed to be . The FDA should be a disinterested third party and has not performed that role well at all in the past .

Report abuse

Posted by carroll09 August 2011 | 13h202011-08-09T13:20:02Z

Related products

Video

02-Dec-2014 - For food manufacturers, Kikkoman Sales USA, Inc. is much more than a soy sauce company. We are a partner in flavor formulation and we have some fresh solutions that will surprise you. Kikkoman provides flavor versatility and a label consumers...

Technical / white paper

02-Mar-2015 - With the uptrend in protein-packed applications and increasing allergen awareness, meat protein can be a desirable alternative to plant- and dairy-based proteins. This white paper compares meat proteins – specifically, concentrated chicken protein – to other common proteins, and outlines...

Event programme

08-Dec-2014 - Leaders in R&D, marketing and business strategy who are passionate about innovation and growth come together at Food Vision in Cannes to debate the sources of sustainable growth and profitability in today's global nutrition, food & drink markets. Food Vision...